白雲山(00874.HK)擬註冊發行不超30億元中期票據
格隆匯7月8日丨白雲山(00874.HK)公佈,於2020年7月8日,公司董事會會議審議通過關於提請股東大會授予公司發行中期票據一般性授權的議案,同意提請股東大會一般及無條件授權公司在中國銀行間交易商協會申請註冊發行總額度不超過人民幣30億元的中期票據,在註冊有效期內分期擇機發行事宜。同時,為簡化手續,公司提請股東大會授權公司管理層根據市場實際情況決定發行的相關事宜,包括但不限於確定實際發行的金額、利率、期限、發行對象、募集資金用途等,並授權董事長在上述董事會和股東大會批准的額度範圍內簽署相關文件。本項授權的有效期為自股東大會批准之日起36個月。
審議通過關於提請股東大會授予公司下屬控股子公司廣州醫藥股份有限公司發行中期票據及超短期融資券一般性授權的議案,同意提請股東大會一般及無條件授權公司下屬控股子公司-廣州醫藥股份有限公司(“醫藥公司”)在中國銀行間交易商協會申請註冊發行總額度分別不超過人民幣16億元的中期票據及人民幣20億元的超短期融資券,在註冊有效期內分期擇機發行事宜。本項授權的有效期為自股東大會批准之日起36個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.